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Abstract
Background: The World Health Organization (WHO) has included comorbidity between depression and a chronic
disease among the 10 leading global health priorities. Although there is a high prevalence of multimorbidity, health
care systems are mainly designed for the management of individual diseases. Given the difficulty in delivering face-
to-face psychological treatments, alternative models of treatment delivery have been proposed, emphasizing the
role of technologies such as the Internet. The aim of this study is to assess the efficacy in Primary Care (PC) of a
blended low-intensity psychological intervention applied using information and communication technologies (ICTs)
for the treatment of multimorbidity in PC (depression and type 2 diabetes/low back pain) by means of a
randomized controlled trial (RCT). Our main hypothesis is that improved usual care combined with psychological
therapy applied using ICTs will be more efficacious for improvement in the symptomatology of multimorbidity,
compared to a group with only improved treatment as usual six months after the end of treatment.
Methods: A protocol has been designed combining a face-to-face intervention with a supporting online
programme that will be tested by an RCT conducted in three different regions (Andalusia, Aragon and the Balearic
Islands). The RCT will evaluate three hundred participants diagnosed with depression and type 2 diabetes/low back
pain. Four highly experienced research groups specializing in clinical psychology are involved in this trial, and there
will be ample possibilities for translation and transfer to usual clinical practice.
Discussion: This clinical trial will lead to improvement in financial sustainability, maximizing the use of resources
and responding to principles of efficiency and effectiveness. Furthermore, based on the evaluation of the feasibility
of implementing this intervention in primary care facilities, we expect to be able to suggest the intervention for
incorporation into public policy. In conclusion, positive results of this study could have a significant impact on one
of the most important health-related problems, multimorbidity.
Trial registration: ClinicalTrials.gov, NCT03426709. Registered retrospectively on 08 February 2018.
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Background
Multimorbidity, the presence of two or more medical con-
ditions of long duration, is a prevalent finding, reaching
levels of approximately 23% in European countries and in-
creasing with age until it constitutes the norm in people
aged 65 years and over [1]. However, the structure of
health systems and those of medical research and educa-
tion is designed for the prevention, treatment and man-
agement of isolated diseases and not multimorbidity.
The only meta-analysis to look at the efficacy of comor-
bidity treatment analysed 9 randomized controlled trials
(RCTs), most of them in elderly patients [2]. The interven-
tions consisted of a change in the provision of care (case
management or interdisciplinary collaboration) or
patient-oriented interventions. Information and commu-
nication technologies (ICTs) were not used in any of the
cases. The results indicate that it is difficult to improve
outcomes in this population, but those interventions that
focus on specific risk factors or difficulties may be more
effective. An important limitation in the literature is that
no cost-effectiveness studies were included, nor was there
any inclusion of qualitative studies attempting to under-
stand the barriers in the interaction between health sys-
tems and patients [2]. In addition, changes in the
provision of medical services are more complex and
costly, making them less sustainable over time than per-
sonalized interventions. However, forms of personalized
intervention based on ‘stepped care’ models and using
ICTs have not been evaluated in multimorbidity.
Current guidelines for the treatment of comorbidity
emphasize the need to personalize treatment, after an in-
dividualized evaluation of the disorders and their context,
as well as to negotiate the therapeutic goals with the pa-
tients and re-evaluate them throughout the process, a
process denominated the ‘Ariadne Principles’ [3]. All of
this requires communication skills and time availability
which not always possible in current health systems [4].
Therefore, complementary strategies are required to
support general practitioners (GPs) in the provision of
personalized and appropriate care to these patients [1].
The few studies published on multimorbidity in Spain,
mainly in the elderly population, confirm that the negative
impact on quality of life and disability is largely caused by
mental disorders [5], more specifically depression [6]. This
represents an important worldwide public health problem,
as it is estimated that it will be the second leading cause of
disability in the world by 2020 [7], with a very high eco-
nomic cost [8]. Owing to its huge prevalence, 13.9–29% in
primary care (PC) [9], international health authorities con-
sider that available economic resources will be unable to
meet the psychological treatment needs of this population
[10]. For this reason, innovative and cost-effective alterna-
tives that make use of ICTs for the treatment of depres-
sion and involve minimal face-to-face services are being
proposed. The use of ICTs has proven effective both for
depression and different mental health problems [11].
Therefore, prestigious organizations such as the National
Institute of Clinical Excellence (NICE) in the UK have in-
cluded in their guide [12] for online treatments such as
Beating the Blues to treat depression.
Meta-analyses confirm that the two interventions of first
choice for depression are pharmacotherapy and/or psy-
chotherapy. The results are similar in the short term, but
higher in the long term for psychological treatments, with
lower dropout rates and fewer relapses [13, 14]. Different
national and international clinical guidelines [12, 15] have
proposed a stepped care model in PC, whereby a large
proportion of patients are treated first with low-intensity
interventions, with significant clinical benefits. In depres-
sion, low-intensity interventions are offered to patients
with mild or moderate depressive symptoms.
The World Health Organization (WHO) has included
comorbidity between depression and a chronic medical
disease among the 10 leading global health priorities [5].
The comorbidity between depression and somatic illness
means a significant increase in the disease burden since
it implies a greater number of symptoms, higher mor-
bidity, higher health care costs and a worse functioning
and quality of life [16]. Current evidence supports a bi-
directional relationship between depression and medical
illness [17]. The suggested mechanisms to explain this
complex relationship would include both biological as-
pects and behavioural variables. Depression is also asso-
ciated with worse adherence to treatment in patients
with comorbidity, for example, in antihypertensive or
diabetes treatment [18, 19].
As regards medical conditions, although hypertension
is highly prevalent (50–60%) [5], the most disabling con-
ditions are osteoarticular diseases, diabetes and cerebral
infarction [5, 6]. Therefore, the study will focus on two
physical conditions comorbid to depression that involve
the greatest disability, loss of quality of life and higher
health costs: diabetes and chronic pain.
In 2013, the International Diabetes Federation (IDF)
[20] reported that 382 million people in the world had
diabetes, estimating that 592 million people will have
diabetes by 2035, which would mean an increase of 55%.
In terms of healthcare provision, it is estimated that in
2013, 548 billion dollars were spent worldwide on the
care of diabetes and its complications, a rate that will in-
crease over the years. The risk person with diabetes has
of suffering from depression is approximately double
that of a person without diabetes [21]. One in four pa-
tients with diabetes has depression [22], with higher
mortality in these patients [23], and therefore depression
and diabetes should be treated together and not as iso-
lated diseases [23]. A review on the effectiveness of de-
pression treatments in patients with diabetes [24]
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confirmed that it is effective, more specifically psycho-
therapy combined with self-care education for patients,
with improvements shown in both psychological vari-
ables and glycaemic control.
Finally, the comorbidity of depression and chronic pain
is extremely high in PC (56%) and reaches even higher
rates in secondary care (50–69%) [25]. Given the high
level of disability associated with the comorbidity of
chronic pain and depression, and regardless of the direc-
tion of this association, national guidelines and consensus
[15, 25] indicate the need to perform an objective assess-
ment of pain in patients with depression by means of vali-
dated instruments. In addition, they establish that an
integral therapeutic intervention should be considered,
contemplating pharmacological and non-pharmacological
treatments. The most common pain affects the lumbar
skeletal muscle and is of mechanical origin, and almost
the entire population suffers from it sometime in their life
[26]. Together with depression, they lead the ranking of
global disability caused by diseases [27]. Clinical guidelines
recommend a treatment that includes education, physical
exercise, physiotherapy and acupuncture [28]. However,
there is not enough evidence on long-term results or on
the superiority of any of these treatments over others [29–
31]. A recent systematic review with meta-analysis has
found long-term superiority of cognitive behavioural ther-
apy compared to other therapies in relation to pain, dis-
ability and quality of life [32]. Despite the advantages that
they could bring, there are no studies on the application
of ICTs to either multimorbidity or any of the medical
conditions included in this study [33].
The aim of this study is to evaluate the effectiveness in
PC of a blended low-intensity psychological intervention
applied through ICTs in the treatment of multimorbidity in
PC (depression and type 2 diabetes / low back pain) in an
RCT. Our main hypothesis is that the treatment-as-usual
intervention, enhanced through the delivery of
low-intensity psychological therapy by ICTs, will be more
effective for the improvement of the symptomatology of
multimorbidity in PC, in relation to a group with
treatment-as-usual only, measured at 6months after com-
pletion of the treatment.
Methods
Study design
This study is a two-armed and multicentre RCT, coordi-
nated by the Aragon’s group. Participants will be randomly
allocated to one of two conditions: a) low intensity
Internet-delivered psychological intervention and b) im-
proved treatment-as-usual (iTAU) groups in primary care.
Setting and study sample
Participants will be recruited from PC health centres in
the three Spanish regions participating in the study
(Andalusia, Aragon and the Balearic Islands) from pa-
tients who meet the inclusion criteria and to whom the
characteristics of the study will be explained. Patients
will be recruited by GPs working in these PC centres
until the required sample is completed, with a quota of
100 patients assigned to each centre. The inclusion and
exclusion criteria are given in Table 1.
Sample size
The sample size of this study was based on the possibility
of detecting differences between the intervention
programme versus treatment-as-usual, for a difference in
the main variable of at least 0.5 standard deviations. This
effect size was obtained from other studies, and it is
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Minimum age of 18 years Any diagnosis of a disease that may affect the central nervous system
(brain condition, traumatic brain injury, dementia, etc.)
DSM-5 diagnosis of Major Depression or persistent depressive disorder,
mild or moderate depression expressed as a score lower than 14 in the
Patient Health Questionnaire (PHQ-9)
Other psychiatric diagnoses or acute psychiatric illness (substance
dependence or abuse, history of schizophrenia or other psychotic
disorders, eating disorders, etc.), except for anxiety disorder or
personality disorders
Ability to understand oral and written Spanish Any medical, infectious or degenerative disease that may affect mood
Willingness to participate in the study and signing informed consent Presence of delusional ideas or hallucinations whether consistent or
not with mood
Duration of depressive symptoms 2months or more Suicide risk
Diagnosis of one of the following two conditions:
- Type 2 Diabetes (Diagnosis according to criteria of the American
Diabetes Association, ADA)
- Lower back pain (Diagnosis of non-specific chronic low back pain
according to the definition established by the CPG COST B-13 with
a duration of at least 6 months)
Possession of and ability to use a computer, an Internet connection
and a mobile phone
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considered a clinically relevant criterion [34, 35]. Assum-
ing equal variance between the groups, a power of 80%,
and a level of significance of 5%, 63 subjects were esti-
mated for each group. To be able to compare the subjects
treated with the specific intervention versus those receiv-
ing with treatment-as-usual only, as well as depending on
the conglomerate to which they belong (each disease
group), 4 groups were estimated with 63 subjects in each
one, with a total of 252 subjects. An experimental mortal-
ity loss of 15% was estimated [36, 37], so the required size
was finally 300 subjects (100 at each PC centre).
Recruitment
Participants will be recruited in PC settings by participat-
ing GPs from patients fulfilling study criteria. When po-
tential patients are identified by a GP, the characteristics of
the study will be explained to them, and if the patients are
interested in participating, they will be asked to sign an in-
formed consent. The GPs will complete referral forms, in-
dicating that the patients meet the criteria and will provide
a brochure to present the study and an information sheet.
The GPs will send the referrals and the patients’ signed
consent forms by e-mail to the local researcher. The asses-
sor researcher will contact the participants to agree on the
established evaluation times. Some patients may prefer to
postpone their decision to participate in the study, in
which case they will be provided with information about
the study by their GPs and how to contact the research
team (by phone, email, or by leaving their information on
the website).
The assessor researcher will clarify any doubts, ensure
that the participants have read the information about the
study, and make sure that they have understood the two
experimental conditions. Then the assessor will determine
their inclusion in the study from the psychological tests
and biological variables related to the inclusion criteria be-
fore contacting an independent researcher to implement
randomization. This researcher will be unaware of the
characteristics of the study. Recruitment will be done con-
secutively until the final sample sizes are reached.
Randomization, allocation and masking of study groups
At such a time, the assessor will collect the baseline data
and contact a person independent of the research group
to perform the individual randomization and inform the
assessor of a code that corresponds to the type of treat-
ment (unknown by the assessor) and send it to the re-
searcher with the baseline data. Another independent
person will do the data monitoring with a general practi-
tioner. The randomization will be conducted by blocks
of patients from the three PC centres, with 100 patients
selected from each centre so that 150 patients are ran-
domized into each of the two arms. Participants agree to
their inclusion before finding out the treatment to which
they will be allocated. All participants will be free to
withdraw from the treatment at any time.
Interventions
Internet-delivered psychological intervention
All interventions (except iTAU) comprise two
face-to-face individual sessions and 6 online, individual
and interactive therapeutic modules. Each face-to-face
session will be 90 min in length. The online therapeutic
modules are oriented to work on different psychological
techniques, supported by multimedia material (videos,
audio, etc.), as Internet support, and the duration of
each module will be approximately 60 min.
The content of the modules is explained in depth later.
The structure of the modules always follows the same
scheme: each begins with the explanation of the contents
of the module, different exercises are proposed, and then
the self-test questions are presented to verify whether the
explanation has been understood. If any user does not cor-
rectly answer any question, the computer program will
immediately provide the correct feedback with a simple
explanation. The module ends with the proposal of home-
work with the aim of practising what has been learned. In
addition, before starting each module, a check is made to
see whether the participants have carried out the proposed
tasks and responds by congratulating them or encouraging
them to do the task. It is very important to carry out these
tasks in order to consolidate everything learned in the
programme and so that the strategies offered by the
programme are turned into skills. An important aspect is
the possibility of reviewing the content of the different
modules. The programme is designed to last 8–12 weeks.
After some time without accessing the computer program
(a time that can be programmed), the user will receive a
reminder e-mail to continue completing the modules. The
clinician can modify the period that should pass without
entering to receive said reminder. The programme con-
tents are the following:
– Face-to-face session 1. Presentation of the
programme: Motivational techniques will be used to
increase adherence of participants to face-to-face ses-
sions and homework, and adherence to pharmacological
treatment will be also promoted as one of the main focal
points of the programme. The online computer program
will be presented and patients will be trained in the pro-
cedure to log in and use it from home.
– M1. Psychoeducation of depression: The impact of
depression on patients’ quality of life and
functional ability, as well as on the prognosis of
diabetes and other chronic diseases, will be
described. The initial symptoms of depression and
how to respond when they appear will be
analysed. Self-control under stress will be
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emphasized, with patients taught to do relaxation
exercises and to reward efforts and achievements
made. In addition, specific techniques and very
useful and practical tips to reduce stress in daily
life will be explained.
– M2. Healthy Life Style: The need to carry out
regular physical activity will be explained. The
Mediterranean diet will be introduced, with
education on the need to follow 6 healthy dietary
commands. All of this will come with information
and practical exercises on how to systematize food-
related behaviours. Developing a social support
network will be emphasized. People will be shown
specific techniques on how to create and maintain
an adequate social support network.
– M3. Behavioural activation: The importance of
establishing and maintaining an adequate level of
activity and involvement with life will be considered.
Patients will be taught to schedule activities, and the
need to monitor the performance of significant
activities will be explained. The essential tool of this
module will be the ‘Activity Diary’.
– M4. Positive psychology: This module will help
patients to see the importance of positive emotions
and learn procedures that generate positive
experiences, encouraging involvement in pleasant and
meaningful activities and contact with other people.
– M5. Mindfulness and compassion: This module will
include components of Mindfulness-based Cognitive
Therapy (MBCT). Core mindfulness practices will
be carried out: the practice of breathing, the body
scan and the 3-min exercise. The importance of es-
tablishing a regular mindfulness practice, as well as
regular informal practice, will be considered. Some
basic elements of compassion will be included, such
as the self-compassionate pause.
– Face-to-face session 2. Review of completed modules
already and practice. This is a structured session
comprising: a) resolution of doubts, b) performing
some of the most important practices (proposed to
be done periodically at home), c) emphasizing the
continuous putting into practice of the strategies
learned and d) farewell and intervention closure.
– M6. Relapse prevention and maintenance: This
module aims to strengthen the strategies learned
during the programme. The possibility of continuing
to practice the strategies learned once the treatment
is completed will also be discussed, with emphasis
on the fact that participants can continue to use the
online computer program during the entire follow-
up period (6 months) for this purpose. It will also
teach participants how to identify and cope with fu-
ture high-risk situations. Finally, instructions will be
given to conduct follow-up evaluations.
This group of patients will also receive iTAU from
their GPs, as described in the next paragraph.
iTAU at primary care level
All the patients included in the study (whether they re-
ceive the Internet-delivered psychological intervention or
not) will be also treated by their GPs. In practice,
treatment-as-usual in PC is any kind of treatment admin-
istered by the GP to the patient with depression. However,
this treatment in primary care will be improved because
the participating GPs will receive a training programme
on the widely used Spanish Guide for the Treatment of
Depression in Primary Care, which is based on the NICE
guidelines on subject [15]. In case of suicide risk, severe
social dysfunction or worsening of symptoms, it is recom-
mended that patients are referred to mental health facil-
ities [38]. For both groups, the use of health and social
services – including consultations with professionals,
pharmaceutical use and other resources, will be registered
using the Client Service Receipt Inventory (CSRI) [39].
Instruments
The assessor will be blind to the type of treatment that
will be administered to patients. In addition, this assessor
will be different from the person who collects the mea-
surements of the study results. As far as possible, GPs will
also be blind to the intervention arm to which each pa-
tient is allocated, since their intervention should be based
only on usual practice, based on the criteria set out in the
Guide for the Treatment of Depression in Primary Care.
Patients will be assessed at baseline (post-randomiza-
tion), after the treatment, and at 3-month and 6-month
follow-ups, in order to test whether the improvements
achieved during the therapy are maintained in the long
term. The study variables assessed are summarized in
Table 2. The study flowchart is shown in Fig. 1.
Main outcome
According to the objectives of the study, the primary
outcome will be a composite that considers the following
variables:
Depressive symptom severity will be assessed via the
Patient Health Questionnaire (PHQ-9) [40] using the
Spanish validated version [41]: Percentage of patients
with reduction ≥2 points. The PHQ-9 [40], validated
Spanish version [41] is one of the questionnaires that
assess the intensity of depression most widely used in
pharmacological and psychological studies. It is a brief
and self-applied scale whose objective is to help diagnose
depression (DSM-IV criteria) and determine its severity.
Similarly, it is also useful to monitor changes experi-
enced by patients over time. It will be taken four times:
at baseline, post-treatment, and at 3-month and
6-month follow-ups.
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Control of diabetes will be measured by VR d = glyco-
sylated haemoglobin (% ≤ 7 or % with a decrease of 0.50
baseline), HbA1c, fasting capillary blood glucose, weight
(kg), height (cm), waist circumference (cm), and abdom-
inal diameter (cm).
Pain intensity and physical limitation will be mea-
sured. Pain intensity will be assessed via the Faces
Pain Scale – Revised (FPS-R) [42], a self-report meas-
ure in which the patient scores the chosen face with
0, 2, 4, 6, 8, or 10, counting from left to right, where
0 = no pain, and 10 = very much pain. Disability will
be assessed via Roland-Morris Scale [43]: This scale is
designed to reliably determine the level of physical
disability resulting from non-specific low back pain.
In this regard, ‘physical disability’ is defined as the
limitation in the performance of daily activities be-
tween 0 (absence of disability for back pain) and 24
(maximum possible disability). A change in score only
has clinical relevance if it is of 2 or more points, al-
though the optimal threshold is between 3 and 4
[44–46]. VR d = % with decrease ≥2 points.
The composite would be weighted to give 1/3 or 1/2
to each of the main measures of depression, diabetes
and pain, obtaining an aggregate score. The calculation
of the weighting of the composite variables would be
performed by means of multiple regression.
Secondary outcomes
Sociodemographic variables The following sociodemo-
graphic data will be collected: gender, age, marital status
(single, married/long-term relationship, separated/
divorced, widowed), education (years of education), oc-
cupation and economical level.
Mini-International
Neuropsychiatric interview (MINI) This is a short
structured diagnostic psychiatric interview that yields
key DSM-IV and ICD-10 diagnoses [47]. The MINI can
be administered in a short period of time and clinical in-
terviewers only need brief training. The MINI has been
translated into Spanish and the Spanish version validated
[47]. This psychiatric interview will allow the diagnosis
of depression to be made at baseline in the study.
SF-12 Health Survey This is an instrument that mea-
sures the state of perceived health. It consists of 12
items that measure 8 dimensions. The calculation of
the scores is based on reference standards, on a scale
of 0 (worst possible health status) to 100 (best pos-
sible health status). The SF-12 has good psychometric
qualities [48] and is validated in Spanish [49].
CSRI Spanish version [39, 50] Questionnaire for col-
lecting information about the use of health and social
care services and other economic impacts (such as time
off work due to illness). The variant used in this study
was designed to collect retrospective data on service
utilization during the 12 previous months.
EuroQol-5D-3 L (EQ-5D-3 L) [51] The utility scores
were obtained from the EuroQol-5D (EQ-5D) classifica-
tion system, which measures health-related quality of life
on a scale of 0 (as bad as death) to 1 (perfect health).
Table 2 Study variables
Instrument Assessment area Time to assessment Applied by
PHQ-9 (40, 41) Severity of depression Baseline and follow-up sessionsa Researcher A phone
Online (follow-up sessionsa)
Glycosylated haemoglobin Diabetes control Baseline and follow-up sessionsa Online
FPS-R [42] Pain intensity Baseline and follow-up sessionsa Online
Roland-Morris Scale [43–46] Physical limitation Baseline and follow-up sessionsa Online
MINI [47] Psychiatric diagnosis Baseline Researcher A phone
Sociodemographic data Gender, age, marital status, education,
occupation, economical level
Baseline Researcher A phone
SF-12 Health Survey [48, 49] Health-related quality of life Baseline and follow-up sessionsa Online
CRSI [39, 50] Health and social services use Baseline and 6months post-treatment Researcher A
phone (Baseline)
Researcher B phone
(6 months post-treatment)
EQ-5D-3 L [51, 52] Quality of life related to health Baseline and follow-up sessionsa Online
OFS [53] Baseline and follow-up sessionsa Online
PHQ-9 Patient Health Questionnaire, FPS-R Faces Pain Scale –Revised, MINI Mini-International Neuropsychiatric Interview, CSRI Client Service Receipt Inventory,
EQ-5D-3 L EuroQol-5D-3 L, OFS Openness to the Future Scale
aFollow-up sessions: post-treatment, 3 and 6 post-treatment months
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However, this two-part index may also provide negative
values that correspond to health states perceived as
worse than death. Part 1 records self-reported problems
in each of five domains: mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression. Part 2 re-
cords the subject’s self-assessed health on a visual
analogue scale (VAS), a 10-cm vertical line along which
the best and worst imaginable health states are scored
between 100 and 0, respectively. The utility scores for
these health states were assigned using the Spanish
population rates [52].
Openness to the Future Scale (OFS) [53] This 10-item
instrument measures positive affectivity towards the
future that can be a prospective protective factor for
mental health and an indicator of psychological adjust-
ment. The scale presents good psychometric properties
in a Spanish sample.
Ethical aspects
Informed consent will be obtained from the participants
before they are aware of the group to which they are to
allocated. Before they give their consent, patients will be
provided with a general overview of the aims and char-
acteristics of the study and the psychological and
pharmacological intervention. Patients in the iTAU arm
will be allowed to take the psychological intervention
programme at the end of the study for ethical reasons.
The study has been developed according to national and
Patients who likely meet
inclusion criteria recruited 
by GPs 
Screening by researchers 
using MINI interview and 
PHQ-9
Randomized allocation of 
participating patients
Intervention group:
iTAU + low intensity internet-
delivered psychological 
intervention 
N= 150
Control group:
iTAU 
N= 150 
Recruited patients
Included patients
Monitoring: baseline 3 
and 6 months
Recruited patients
Included patients
Monitoring: baseline 3 
and 6 months
- Attrition
- Ineligibility
- Attrition
- Ineligibility
Fig. 1 Flowchart of the study: Randomization, sampling and monitoring of patients
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international standards (Helsinki and Tokyo Conven-
tion). Given that the interventions involve the use of the
Internet, an important ethical issue is data protection.
Advanced Encryption Standard (AES) strategies regard-
ing data encryption and use of personal passwords will
be implemented in order to guarantee the protection of
personal information. The data will be treated anonym-
ously and will only be used for the purposes of the study.
The confidentiality of the participants included in the
study will be guaranteed. Finally, the study protocol was
approved by the Research Ethics Committee of each au-
tonomous community: (CEICA in Aragon, CEIC in the
Balearic Islands and the Regional Ethics and Research
Committee of the province of Malaga, Andalusia).
Analysis strategy
Analysis of clinical efficacy
Intention-to-treat and per-protocol analysis will be used.
Analysis will include the description and ‘head-to head’
comparison between the two groups. Descriptive statis-
tics of the included variables (mean and 95% confidence
interval for normally distributed quantitative variables;
and median and interquartile range for abnormally dis-
tributed quantitative variables) will be performed. To
confirm the main hypothesis, all variables will be com-
pared (t0-tk) using an analysis of variance (ANOVA)
and post-hoc tests or Kruskal-Wallis non-parametric
tests. Finally, more sophisticated multivariate analysis,
including multilevel regression, will be used. The effect
size of improvement and the number needed to treat
(NNT) in each arm will be estimated.
Descriptions of costing procedure
Data collection on the use of health and social ser-
vices will be collected through the CSRI-Spanish ver-
sion [39, 50]. Costs of the study will be estimated
from the healthcare and societal perspectives during
the previous six months (before baseline), and during
the six months of follow-up. Direct health care costs
will be calculated by adding the costs derived from
pharmacological consumption, use of health services
and clinical tests, and costs incurred by the staff run-
ning the intervention.
The cost of medication will be calculated by determin-
ing the price per milligram during the study, according
to the databases of the Spanish Ministry of Health and
Consumer Affairs, including value-added tax. The total
cost of medication will be calculated by multiplying the
price per milligram by the daily dose in milligrams and
the number of days of treatment. The main source of
the unit cost data for medical tests and health services is
the OBLIKUE database of health care costs [54]. The
OBLIKUE database contains information about Spanish
health service costs and is derived by systematic reviews
of the literature. Indirect costs (lost productivity) will be
calculated considering sick leave days and multiplying
them by the minimum daily wage in Spain for 2018.
Finally, total costs will be calculated by adding direct
and indirect costs. The unit costs will be expressed in
euros (€), based on 2018 prices.
The two interventions in this study will be conducted
by government agencies and financed by the Carlos III
Health Institute; their implementation will not incur
additional costs for the Spanish National Health Service.
Therefore, costs associated with the interventions in the
study will not be included.
The economic evaluation of this study will follow the
general guidelines for conducting pharmacoeconomic
analyses in Spain. It will also follow the Guidelines of
the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) [55] and the Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) [56].
Utility scores
Utility scores will be obtained from two health-related
quality of life questionnaires EuroQol 5D and SF-12.
QALYs will be calculated based on these scores using
the Spanish EQ-5D tariffs [57]. Along with EQ-5D utility
scores, scores recorded on the EQ VAS will also be used
as an outcome for the analysis.
The perspective used in our analysis will be twofold:
the social perspective, to include all costs and quality of
life, and the perspective of the Spanish health system.
The time horizon of the study is six months, so it will
not be necessary to apply a discount factor to the costs.
Cost-utility analysis
Cost-effectiveness will be explored through the calcula-
tion of incremental cost-effectiveness ratios (ICERs) for
the intervention group using the iTAU group as the con-
trol. To estimate the ICER (ratio between incremental
costs and incremental effectiveness) the following equa-
tion will be used:
ICER ¼ Cost active intervention group‐Cost control intervention group
Effectiveness or Utility active intervention group‐Effectiveness or Utility control intervention group
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Effectiveness or Utility active intervention group‐Effectiveness or Utility control intervention group
Cost-utility will be explored through the calculation of
incremental cost-utility ratios (ICURs), which are defined
as the ratio between incremental costs and incremental ef-
fects measured on QALYs [58]. QALYs will be approxi-
mated by using the area-under-the-curve technique.
Data collection will be performed using Excel software
and statistical analysis will use SPSS (SPSS Inc., Chicago,
IL, USA) software version 20, licensed by the University of
Malaga.
Frequency and proportions will be used for descriptive
statistics of categorical or qualitative variables. For quan-
titative variables, the mean and standard deviation will
be obtained.
Inferential statistical analysis will use the Chi-square
test for qualitative variables, one-way ANOVA test for
qualitative and quantitative variables and Student’s t-test
for quantitative variables. In all cases, statistical signifi-
cance will correspond to a value of p < 0.05.
Forecast execution dates
Initial recruitment of patients: September 2018.
Finalization of patient recruitment: April 2019.
Finalization of patient monitoring period: April 2020.
Publication of results: October 2020.
Discussion
The presence of multimorbidity makes it difficult for pa-
tients to seek help, receive a conclusive diagnosis, receive
quality care and adherence to treatment. The present
study proposes the evaluation by means of a leading and
novel intervention in the field of ICTs of disorders of high
prevalence and producing great disability, such as the
multimorbidity between depression and type 2 diabetes/
chronic low back pain. In addition, in a PC setting, where
these patients with a great need for healthcare provision
are increasingly attended. The aim is to evaluate the ef-
fectiveness and cost-effectiveness of this treatment in the
management of depression with medical comorbidity, as
well as to achieve maximum impact for the Spanish Na-
tional Health System, generating knowledge that can be
included in the clinical guidelines for multimorbidity
treatment in PC and throughout the health system.
It should be noted that this is the first study of its kind to
use ICTs in the treatment of multimorbidity. It is also the
first treatment for multimorbidity in Spain. This study has
several strengths: it follows the guidelines of comorbidity
treatment (Ariadne’s Principles); it will be conducted on a
wide age range – most similar studies have been carried out
on a geriatric population, but non-geriatric patients will also
be included, facilitating preventive and health promotion as-
pects. In order to overcome one of the limitations described
in meta-analyses preformed on previously published works,
it includes a cost-effectiveness study; finally, the results ob-
tained from this study can be easily transferred to the health
system through the modification of the current management
given to this group of conditions.
No particular difficulties are expected as regards the re-
cruitment of patients with depression or their participa-
tion in the study. The negative attitudes of some GPs may
hinder their recommending this treatment, therefore a
training session on the study will be held at the participat-
ing PC health centres for professionals interested in par-
ticipating. The main limitation of the study may be a
significantly greater rate of dropouts in the treatment
groups (40% in previous studies). Efforts will be made to
maintain dropout rates in the range of 30% in order to
overcome this limitation. In any case, an associated quali-
tative study will be included with this study to analyse the
barriers and limitations of this therapy on Spain’s public
health system. On the other hand, in addition to the
intention-to-treat analysis, an analysis per protocol will be
performed to determine the efficacy of the intervention in
those patients who do not abandon the treatment.
The treatment programmes used in this study includes
therapeutic strategies (mindfulness, healthy lifestyle habits,
positive psychology and behavioural activation) that have
proven their efficacy for depression, type 2 diabetes and
chronic low back pain treatment [13, 14, 23, 24, 28]. Fur-
thermore, this intervention will lead to improved financial
sustainability, maximizing the use of resources and
responding to principles of efficiency and effectiveness. In
conclusion, the positive results of this study could have a
significant impact on one of the most important problems
in the health context: multimorbidity.
Abbreviations
ADA: diagnosis according to criteria of the American Diabetes Association;
AES: Advanced Encryption Standard; CHEERS: Consolidated Health Economic
Evaluation Reporting Standards; CSRI: Client Service Receipt Inventory; EQ-5D-3
L: EuroQol-5D-3 L; GPs: general practitioners; ICERs: incremental cost-
effectiveness ratios; ICTs: information and communication technologies;
ICURs: incremental cost-utility ratios; IDF: International Diabetes Federation;
ISPOR: International Society for Pharmacoeconomics and Outcomes Research;
iTAU: improved treatment-as-usual; MBCT: Mindfulness-Based Cognitive
Therapy; MINI: Mini-International Neuropsychiatric Interview; NICE: National
Institute of Clinical Excellence (UK); NNT: number needed to treat; PC: primary
care; RCT: randomized controlled trial; WHO: The World Health Organization
Acknowledgements
We would like to thank the support received by the Aragon Health Research
Institute (IIS), and the Aragonese Institute of Health Sciences (IACS). We are also
grateful to the Prevention and Promotion of Health Network in Primary Care
(RD16 / 0007/0005) of the Carlos III Health Institute of the Ministry of Economy
and Competitiveness of Spain and was co-financed with the European Regional
Development Fund FEDER the European Union. “A way of making Europe”.
Funding
The first two authors have a FI predoctoral contract awarded by the Institute
of Health Carlos III (ISCIII; FI17/00180) and the Ministry of Education, Culture
and Sports (Spain) (FPU014/04987) at the Institute of Health Research of
Aragon (IIS) of Zaragoza.
Monreal-Bartolomé et al. BMC Psychiatry           (2019) 19:66 Page 9 of 11
This research is financed by a FIS grant from the Carlos III Health Institute of
the Spanish Ministry Economy and Competitiveness (PI16/00962). The
funding body did not play any role in the design of the study, nor will it
play any role in data collection, analysis, interpretation of data or the writing
of manuscripts. The funding body will audit trial conduct.
Availability of data and materials
Not applicable.
Authors’ contributions
JGC co-conceptualized and designed the study. AMB, YLH and JGC wrote the
first draft. FM and AB planned the statistical analysis. CB and RMB made the
adaptation of the programme to its online version, the realization of usability
tests and the maintenance of the technological platform through which all
groups can administer the programme throughout the development of the
clinical trial. AGP has taken care of the training of the clinicians in the clinical
content of the final program and in the aspects related to the online application
throughout the clinical trial. The online therapeutic modules, supported by
multimedia material (videos, audio, etc.), as Internet support, were designed and
elaborated by AGP and JGC are coordinating the study at Aragon, MG at Balearic
Islands, and FM at Andalusia. YLH is particularly involved in the implementation
and conduction of the project and is responsible for the data collection at
Aragon, AC and MAP at Balearic Islands and MMH and EV at Andalusia. RMB, CB,
MG, FM and AGP commented and critically reviewed the manuscript for
important intellectual content. JGC, MG, FM and AGP obtained funding and
supervised all steps. All authors read and approved the final manuscript.
Authors’ information
Not applicable.
Ethics approval and consent to participate
This study is approved by the Research Ethics Committee of each autonomous
community: (CEICA Aragon, CEIC Balearic Islands, and the Regional Ethics and
Research Committee of the province of Malaga) and it is designed in
accordance with the ethical standards laid down in the Declaration of Helsinki
and its later amendments. Written informed consent will be obtained before
screening and application of exclusion criteria takes place.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Primary Care Prevention and Health Promotion Research Network, RedIAPP,
Carlos III Health Institute, Madrid, Spain. 2Aragon Institute for Health
Research, IIS Aragon, Zaragoza, Spain. 3Primary Care Prevention and Health
Promotion Research Network, RedIAPP, Madrid, Spain. 4Institut Universitari
d’Investigació en Ciències de la Salut, IUNICS-IDISPA, University of the
Balearic Islands, Palma, Spain. 5Mental Health Department, Institute of
Biomedicine of Malaga, University Regional Hospital of Malaga, Malaga,
Spain. 6Jaume I University, Castellon de la Plana, Spain. 7CIBER
Physiopathology Obesity and Nutrition (CIBERobn) Carlos III Health Institute,
Madrid, Spain. 8Department of Clinical and Basic Psychology and
Biopsychology, Faculty of Health Sciences, University Jaume I, Castellon,
Spain. 9Department of Psychological, Personality, Evaluation and Treatment,
University of Valencia, Valencia, Spain. 10Department of Psychology and
Sociology, University of Zaragoza, Zaragoza, Spain. 11Instituto de
Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, Zaragoza,
Spain.
Received: 24 July 2018 Accepted: 25 January 2019
References
1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
of multimorbidity and implications for health care, research, and medical
education: a cross-sectional study. Lancet. 2012;380:37–43.
2. Smith SM, Soubhi H, Fortin M, Hudon C, O'Dowd T. Interventions for
improving outcomes in patients with multimorbidity in primary care and
community settings. Cochrane Database Syst Rev. 2012;4:CD006560.
3. Muth C, van den Akker M, Blom JW, Mallen CD, Rochon J, et al. The Ariadne
principles: how to handle multimorbidity in primary care consultations. BMC
Med. 2014;12:223.
4. Starfield B, Lemke B, Bernhardt B, et al. Comorbidity: implications for the
importance of primary care in `Case' Management. Ann Fam Med. 2003;1:8–14.
5. Forjaz MJ, Rodriguez-Blazquez C, Ayala A, Rodriguez-Rodriguez V, de Pedro-Cuesta J,
Garcia-Gutierrez S, Prados-Torres A. Chronic conditions, disability, and quality of life
in older adults with multimorbidity in Spain. Eur J Intern Med. 2015;26(3):176–81.
6. Garin N, Olaya B, Moneta MV, Miret M, Lobo A, Ayuso-Mateos JL, Haro JM.
Impact of multimorbidity on disability and quality of life in the Spanish
older population. PLoS One. 2014;9(11):e111498.
7. Murray CJL, Lopez AD. Alternative projections of mortality and disability by
cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–504.
8. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the
brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1–27.
9. Roca M, Gili M, Garcia-Garcia M, Salva J, et al. Prevalence and comorbidity of
common mental disorders in primary care. J Affect Disord. 2009;119(1–3):52–8.
10. Lehtinen V, Riikonen E, Latineen E. Promotion of Mental Health on the
European Agenda. Report. Finnish Ministry of Social Affairs and Health, Dpt
for Prevention and Promotion, 2000.
11. Andersson G, Cuijpers P, Carlbring P, Riper H, Hedman E. Guided internet-
based vs. face-to-face cognitive behavior therapy for psychiatric and
somatic disorders: a systematic review and meta-analysis. World Psychiatry.
2014;13(3):288–95.
12. National Collaborating Centre for Mental Health. Depression: Management
of depression in primary and secondary care. Rushden: The British
Psychological Society and Gaskell; 2007.
13. Cuijpers P, van Straten A, van Shaick A, Andersson G. Psychological treatment
of depression in primary care: a meta-analysis. Br J Gen Pract. 2009;59:120–7.
14. Gill D, Hatcher S. Antidepressants for depression in medical illness.
Cochrane Database Syst Rev. 2000;4:CD001312.
15. García-Herrera JM, Nogueras-Morillas V, Muñoz-Cobos F, Morales-Asensio
JM: Guía de Práctica Clínica para el Tratamiento de la Depresión en
Atención Primaria [Clinical Practice Guide on the Treatment of Depression
in Primary Care]. Distrito Sanitario Málaga UGC Salud Mental Hospital
Regional Universitario “Carlos Haya”: Málaga; 2011.
16. Gili M, Garcia-Toro M, Vives M, Armengol S, et al. Medical comorbidity in
recurrent versus first-episode depressive patients. Acta Psychiatr Scand.
2011;123:220–7.
17. Holahan CJ, Pahl SA, Cronkite RC, Holahan CK, North RJ, Moos RH.
Depression and vulnerability to incident physical illness across 10 years. J
Affect Disord. 2010;123:222–9.
18. Calderón-Larrañaga A, Diaz E, Poblador-Plou B, Gimeno-Feliu LA, Abad-Díez
JM, Prados-Torres A. Non-adherence to antihypertensive medication: the
role of mental and physical comorbidity. Int J Cardiol. 2016;207:310–6.
19. Gonzalez JS, Peyrot M. McCarl LA, et al depression and diabetes treatment
nonadherence: a meta-analysis. Diabetes Care. 2008;31(12):2398–403.
20. International Diabetes Federation (2013). IDF Diabetes Atlas (Sixth edition).
21. Gili M, Comas A, Garcia-Garcia M, Monzón S, Serrano A, Roca M.
Comorbidity between common mental disorders and chronic somatic
diseases in primary care patients. Gen Hosp Psychiatry. 2010;32(3):240–5.
22. Peyrot M. Depression: a quiet killer by any name. Diabetes Care. 2003;26(10):
2952–3.
23. Lustman PJ, Clouse RE, Ciechanowski PS, Hirsch IB, Freedland KE. Depression
related hyperglycemia in type 1 diabetes: a mediational approach.
Psychosom Med. 2005;67:195–9.
24. van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W,
Snoek F, Sartorius N. Effect of interventions for major depressive disorder and
significant depressive symptoms in patients with diabetes mellitus: a
systematic review and meta-analysis. Gen Hosp Psychiatry. 2010;32(4):380–95.
Monreal-Bartolomé et al. BMC Psychiatry           (2019) 19:66 Page 10 of 11
25. Cervilla JA. Dolor y depresión. En: Bobes J, Giner J, López F, Saiz-Ruiz J,
Zamorano E, editores. Salud física en el paciente con depresión. Madrid:
Fundación Española de Psiquiatría y Salud Mental;2012. p. 199–237.
26. Hoy D, March L, Brooks P, Blyth F, Woolf A, et al. (2014) the global burden
of low back pain: estimates from the global burden of disease 2010 study.
Ann Rheum Dis. 2014;73:968–74.
27. Theo Vos, Ryan M Barber, Brad Bell, (2015) Global, regional, and national
incidence, prevalence, and years lived with disability for 301 acute and
chronic diseases and injuries in 188 countries, 1990–2013: A systematic
analysis for the Global Burden of Disease Study 2013.Lancet 5;386(10010):
2287–323.
28. NICE Clinical Guidelines. Low back pain: early management of persistent
non-specific low back pain. MJ 2009;338:b1805.
29. Chou R. QaseemA, snow V, Casey D, cross JJT, et al. (2007) diagnosis and
treatment of low Back pain: a joint clinical practice guideline from the
American College of Physicians and the American pain society. Ann Intern
Med. 2007;147:478–91.
30. Ferreira ML, Smeets RJ, Kamper SJ, Ferreira PH. Machado LA (2010) can we
explain heterogeneity among randomized clinical trials of exercise for
chronic back pain? A meta regression analysis of randomized controlled
trials. Physical therapy Phys Ther. 2010;90(10):1383–403.
31. Rubinstein SM, van Middelkoop M, Kuijpers T, Ostelo R, Verhagen AP, et al.
(2010) a systematic review on the effectiveness of complementary and
alternative medicine for chronic non-specific low- back pain. Eur Spine J.
2010;19:1213–122.
32. Richmond H, et al. The effectiveness of cognitive behavioural treatment for
non-specific low back pain: a systematic review and metaanalysis. PLoS
One. 2015;10(8):e0134192.
33. van Beugen S, Ferwerda M, Hoeve D, et al. Internet-based cognitive
behavioral therapy for patients with chronic somatic conditions: a meta-
analytic review. J Med Internet Res. 2014;16(3):e88.
34. Blogner HR, de Vries HF. Integration of depresssion and hypertension
treatment: a pilot, randomized controlled trial. Ann Fam Med. 2008;6:295–301.
35. Katon WJ, Lin EHB, Von Korkk M, Ciechanowski P, Ludman EJ, Young B, Peterson
D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with
depression and chronic illnesses. N Engl J Med. 2010;363:2611–20.
36. Anderson G, Cuijpers P. Internet-based and other computerized
psychological treatments for adult depression: a meta-analysis. Cogn Behav
Ther. 2009;38:196–205.
37. Kaltenthaler E, et al. Computerized cognitive-behavioural therapy for
depression: systematic review. Br J Psychiatry. 2008;193:181–4.
38. Herrán A, Rodriguez B, Vazquez Barquero J: Psiquiatría en atención primaria.
In Edited by Vazquez Barquero JL. Madrid: Aula Médica;2007:222–250.
39. Beecham J, Knapp M. Costing psychiatric interventions. In measuring
mental health needs. Edited by Thornicroft G. London: Gaskell; 2001.
40. Kroenke, et al. The PHQ-9: Validity of a brief depression severity measure. J
Gen Intern Med. 2001;16:606–13.
41. Diez-Quevedo C, et al. Validation and utility of patient health questionnaire
in diagnosing mental disorders in 1003 general hospital Spanish inpatients.
Psychosom Med. 2001;63:679–86.
42. Hicks CL, von Baeyer CL, Spafford P, van Korlaar I, Goodenough B. The faces
pain scale – revised: toward a common metric in pediatric pain
measurement. Pain. 2001;93:173–83.
43. Kovacs FM, Llobera J, Gil del real MT, Abraira V, Gestoso M, Fernández C and
the Kovacs-Atención Primaria group. Validation of the Spanish version of
the Roland Morris questionnaire. Spine 2002;27:538–542.
44. Ostelo RW, de Vet HC, Knol DL, van den Brandt PA. 24-item Roland-Morris
disability questionnaire was preferred of six functional status questionnaires
for post-lumbar disc surgery. J Clin Epidemiol. 2004;57:268–76.
45. Stratford P, Binkley J, Solomon P, Finch E, Gill C, Moreland J. Defining the
minimum level of detectable change for the Roland and Morris
questionnaire. Phys Ther. 1996;76(4):359–65.
46. Kovacs FM, Llobera J, Gil Del Real MT, et al. Validation of the Spanish
version of the Roland-Morris questionnaire. Spine. 2002;27:538–42.
47. Ferrando L, Franco L, Soto M, Bobes J, Soto O, Franco L, Gibert J: MINI. MINI
International Neuropsychiatric Interview. Versión en español 5.0.0. Madrid: IAP; 1998.
48. Gandek B, et al. Cross-validation of ítem selection and scoring for the SF-12
health survey in nine countries: results from the SF-12 health survey in nine
countries. J Clin Epidemiol. 1998;51:1171–8.
49. Alonso J, Prieto L, Anto JM. The Spanish version of the SF-36 Health Survey:
an instrument for measuring cinical results. Med Clin (Barc). 1995;104:771–6.
50. Knapp M. PSSRU and Centre for Economics of mental health, Institute of
Psychiatry, University of Kent: economic evaluation of mental health care.
Kent, GB: Ashgate Publishing Group; 1995.
51. Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version
of EuroQol: a description and its applications. European Quality of Life scale.
Med Clin (Barc). 1999;112(Suppl):79–85.
52. Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom
and Spanish general population time trade-off values for EQ-5D health
states. Med Decis Mak. 2001;21(1):7–16.
53. Botella C, Molinari G, Fernandez-Alvarez J, Guillen V, Garcia-Palacios A, Baños R,
Tomás JM. Development and validation of the openness to the future scale: a
prospective protective factor. Health Qual Life Outcomes. 2018;16:72.
54. Oblikue Consulting. Base de Datos de Costes Sanitarios eSALUD. Available
from: http://www.oblikue.com/bddcostes
55. López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al.
Spanish recommendations on economic evaluation of health technologies.
Eur J Health Econ. 2010;11:513–20.
56. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D.
Consolidated health economic evaluation reporting standards (CHEERS)-
explanation and elaboration: a report of the ISPOR health economic
evaluations publication guidelines task force. Value Heal. 2013;16:231–50.
57. Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios
alongside a clinical trial. Health Econ. 2014;3(5):309–19.
58. Romero-Sanchiz P, Nogueira-Arjona R, García-Ruiz A, Luciano JV, García
Campayo J, et al. Economic evaluation of a guided and unguided internet-
based CBT intervention for major depression: results from a multicenter,
three-armed randomized controlled trial conducted in primary care. PLoS
One. 2017;12(2):e0172741.
Monreal-Bartolomé et al. BMC Psychiatry           (2019) 19:66 Page 11 of 11
